Protagenic Therapeutics, Inc. (PTIX)
NASDAQ: PTIX · Real-Time Price · USD
3.390
-0.070 (-2.02%)
At close: Jul 7, 2025, 4:00 PM
3.430
+0.040 (1.18%)
After-hours: Jul 7, 2025, 7:14 PM EDT
Protagenic Therapeutics Market Cap
Protagenic Therapeutics has a market cap or net worth of $20.91 million as of July 7, 2025.
Market Cap
20.91M
Enterprise Value
n/a
1-Year Change
n/a
Ranking
Category
Stock Price
$3.39
Market Cap Chart
Since May 19, 2025, Protagenic Therapeutics's market cap has decreased from $64.38M to $20.91M, a decrease of -67.52%. That is a compound annual growth rate of -99.99%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 3, 2025 | 21.34M | -0.57% |
| Jul 2, 2025 | 21.46M | -1.69% |
| Jul 1, 2025 | 21.83M | -4.32% |
| Jun 27, 2025 | 22.82M | -4.39% |
| Jun 26, 2025 | 23.87M | 5.74% |
| Jun 25, 2025 | 22.57M | - |
| Jun 24, 2025 | 22.57M | 2.52% |
| Jun 23, 2025 | 22.02M | 0.28% |
| Jun 20, 2025 | 21.96M | 3.49% |
| Jun 18, 2025 | 21.22M | -2.27% |
| Jun 17, 2025 | 21.71M | 3.83% |
| Jun 16, 2025 | 20.91M | 2.11% |
| Jun 13, 2025 | 20.48M | -5.68% |
| Jun 12, 2025 | 21.71M | -0.28% |
| Jun 11, 2025 | 21.77M | -0.28% |
| Jun 10, 2025 | 21.83M | -2.75% |
| Jun 9, 2025 | 22.45M | 0.55% |
| Jun 6, 2025 | 22.33M | 3.87% |
| Jun 5, 2025 | 21.49M | -8.29% |
| Jun 4, 2025 | 23.44M | 3.54% |
| Jun 3, 2025 | 22.63M | -3.42% |
| Jun 2, 2025 | 23.44M | -1.30% |
| May 30, 2025 | 23.75M | 1.05% |
| May 29, 2025 | 23.50M | -4.75% |
| May 28, 2025 | 24.67M | 1.52% |
| May 27, 2025 | 24.30M | -17.23% |
| May 23, 2025 | 29.36M | -11.36% |
| May 22, 2025 | 33.12M | -12.54% |
| May 21, 2025 | 37.87M | -10.76% |
| May 20, 2025 | 42.43M | -34.09% |
| May 19, 2025 | 64.38M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 700.84B |
| Johnson & Johnson | 375.37B |
| AbbVie | 334.34B |
| Novo Nordisk | 316.33B |
| UnitedHealth Group | 279.90B |
| Novartis AG | 242.35B |
| Abbott Laboratories | 233.90B |
| AstraZeneca | 218.65B |